Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
Saved in:
| Title: | Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. |
|---|---|
| Authors: | Capra, Ruggero (AUTHOR), Morra, Vincenzo Brescia (AUTHOR), Mirabella, Massimiliano (AUTHOR), Gasperini, Claudio (AUTHOR), Scandellari, Cinzia (AUTHOR), Totaro, Rocco (AUTHOR), De Rossi, Nicola (AUTHOR), Masera, Silvia (AUTHOR), Zipoli, Valentina (AUTHOR), Patti, Francesco (AUTHOR) |
| Source: | Neurological Sciences. Jul2021, Vol. 42 Issue 7, p2837-2845. 9p. 4 Charts, 1 Graph. |
| Subjects: | Labor productivity, Multiple sclerosis, Disease relapse, Natalizumab, Scientific observation |
| Geographic Terms: | Italy |
| Abstract: | Background: The Work Ability in Natalizumab-Treated MS Patients (WANT) study assessed work ability, quality of life, and cognitive processing speed during natalizumab treatment. Methods: WANT was a 1-year, prospective, multicenter observational study conducted in Italy. Inclusion criteria included relapsing-remitting multiple sclerosis (MS), natalizumab treatment, full-time worker status, and loss of working hours due to MS as measured by the Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS). The primary endpoint was change in WPAI:MS domain scores after 1 year on natalizumab. Secondary endpoints included change in annualized relapse rate (ARR), Multiple Sclerosis Impact Scale (MSIS-29) score, and Symbol Digit Modalities Test (SDMT) score. Results: At enrollment, the 91 patients had a mean age of 38.3 (standard deviation [SD], 9.0) years and a mean ARR of 1.5 (SD, 0.8). After 1 year, improvements were observed in all WPAI:MS domains, with significant reductions in Absenteeism (−4.2 [SD, 26.0], p = 0.0190) and Work Productivity Loss (−7.2 [SD, 28.6]; p = 0.0456). These changes were accompanied by a low ARR (0.1), and 87.9% of patients were relapse free. Significant improvement was observed in MSIS-29 physical and psychological domains (reductions of 2.8 [SD, 11.6; p = 0.0295] and 6.3 [SD, 15.6; p = 0.0007], respectively) and SDMT score (increase of 2.4 [SD, 7.9; p = 0.0006]). Adverse events were reported in 32 of 104 patients (30.8%). Conclusions: The reductions in Absenteeism and Work Productivity Loss and the improved physical and psychological functioning reported after 1 year of natalizumab treatment in real-world settings extend our understanding of natalizumab's effects on patient-centric and health economics outcomes. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 151291431 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Capra%2C+Ruggero%22">Capra, Ruggero</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morra%2C+Vincenzo+Brescia%22">Morra, Vincenzo Brescia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mirabella%2C+Massimiliano%22">Mirabella, Massimiliano</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gasperini%2C+Claudio%22">Gasperini, Claudio</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Scandellari%2C+Cinzia%22">Scandellari, Cinzia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Totaro%2C+Rocco%22">Totaro, Rocco</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Rossi%2C+Nicola%22">De Rossi, Nicola</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Masera%2C+Silvia%22">Masera, Silvia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zipoli%2C+Valentina%22">Zipoli, Valentina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Patti%2C+Francesco%22">Patti, Francesco</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Jul2021, Vol. 42 Issue 7, p2837-2845. 9p. 4 Charts, 1 Graph. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Labor+productivity%22">Labor productivity</searchLink><br /><searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+relapse%22">Disease relapse</searchLink><br /><searchLink fieldCode="DE" term="%22Natalizumab%22">Natalizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Scientific+observation%22">Scientific observation</searchLink> – Name: SubjectGeographic Label: Geographic Terms Group: Su Data: <searchLink fieldCode="DE" term="%22Italy%22">Italy</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background: The Work Ability in Natalizumab-Treated MS Patients (WANT) study assessed work ability, quality of life, and cognitive processing speed during natalizumab treatment. Methods: WANT was a 1-year, prospective, multicenter observational study conducted in Italy. Inclusion criteria included relapsing-remitting multiple sclerosis (MS), natalizumab treatment, full-time worker status, and loss of working hours due to MS as measured by the Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS). The primary endpoint was change in WPAI:MS domain scores after 1 year on natalizumab. Secondary endpoints included change in annualized relapse rate (ARR), Multiple Sclerosis Impact Scale (MSIS-29) score, and Symbol Digit Modalities Test (SDMT) score. Results: At enrollment, the 91 patients had a mean age of 38.3 (standard deviation [SD], 9.0) years and a mean ARR of 1.5 (SD, 0.8). After 1 year, improvements were observed in all WPAI:MS domains, with significant reductions in Absenteeism (−4.2 [SD, 26.0], p = 0.0190) and Work Productivity Loss (−7.2 [SD, 28.6]; p = 0.0456). These changes were accompanied by a low ARR (0.1), and 87.9% of patients were relapse free. Significant improvement was observed in MSIS-29 physical and psychological domains (reductions of 2.8 [SD, 11.6; p = 0.0295] and 6.3 [SD, 15.6; p = 0.0007], respectively) and SDMT score (increase of 2.4 [SD, 7.9; p = 0.0006]). Adverse events were reported in 32 of 104 patients (30.8%). Conclusions: The reductions in Absenteeism and Work Productivity Loss and the improved physical and psychological functioning reported after 1 year of natalizumab treatment in real-world settings extend our understanding of natalizumab's effects on patient-centric and health economics outcomes. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=151291431 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10072-020-04838-z Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 2837 Subjects: – SubjectFull: Labor productivity Type: general – SubjectFull: Multiple sclerosis Type: general – SubjectFull: Disease relapse Type: general – SubjectFull: Natalizumab Type: general – SubjectFull: Scientific observation Type: general – SubjectFull: Italy Type: general Titles: – TitleFull: Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Capra, Ruggero – PersonEntity: Name: NameFull: Morra, Vincenzo Brescia – PersonEntity: Name: NameFull: Mirabella, Massimiliano – PersonEntity: Name: NameFull: Gasperini, Claudio – PersonEntity: Name: NameFull: Scandellari, Cinzia – PersonEntity: Name: NameFull: Totaro, Rocco – PersonEntity: Name: NameFull: De Rossi, Nicola – PersonEntity: Name: NameFull: Masera, Silvia – PersonEntity: Name: NameFull: Zipoli, Valentina – PersonEntity: Name: NameFull: Patti, Francesco IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: Jul2021 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 15901874 Numbering: – Type: volume Value: 42 – Type: issue Value: 7 Titles: – TitleFull: Neurological Sciences Type: main |
| ResultId | 1 |
